Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) yesterday announced its entry into a collaboration and licensing agreement with Canntab Therapeutics Limited, developer of a patent-pending oral sustained release formulation for cannabinoids. Per the terms of the agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of this sustained release product, with Emblem receiving the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing and commercializing the innovative product under the Emblem brand. Manufacture of the sustained release product is expected to be completed by Emblem or Canntab following Canntab’s reception of appropriate licensing allowing for such operations. The licensing agreement calls for Emblem to make payments to Canntab upon achievement of certain milestones involving stability studies, bio-availability studies and regulatory approval of the sustained release product. Additionally, Emblem will be responsible for royalty payments to Canntab based upon gross sales of the product.
To view the full press release, visit http://cnw.fm/5Uczn
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.EmblemCannabis.com
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…
Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call…
CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70…
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that…